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ABSTRACT

Dinh, Kristie Nhi. M.S., Department of Biological Sciences, Wright State University,
2021. Interleukin-2 Receptor Alpha Nuclear Localization Impacts Vascular Smooth
Muscle Cell Function and Phenotype.
Atherosclerosis is responsible for 50% of all deaths in western society and is the
main cause of cardiovascular diseases (Pahwa et al. 2020). Vascular smooth muscle cells
(VSMC) play a vital role in the development of atherosclerotic plaques; this is due to
their ability to proliferate and migrate in response to inflammation and damage to
arteries’ inner linings. To further understand what causes these cells to proliferate and
migrate, our lab has previously found that VSMC express all three subunits of the IL-2
receptor (IL-2R). Out of these three subunits, IL-2Rα appeared to change the most
depending on the phenotype of the cell. Our studies have shown that IL-2Rα could play a
vital role in VSMC switching from a proliferative phenotype to a quiescent phenotype, in
response to injury and inflammation.
The present studies found that not only does the nuclear localization of IL-2Rα
impact VSMC proliferation, but that commercially available knockout mice are not fully
knocked out. In the first study, we utilized immunofluorescent staining, western blotting,
and proliferation and migration assays to show that, when IL-2Rα localizes to the
nucleus, VSMC proliferation is inhibited, therefore providing a possible means for
regulation. In the second study, we used similar methodology in addition to PCR to show
that IL-2Rα knock out mice are not completely devoid of IL-2Rα. Because the IL-2Rα
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knock out was generated using a neomycin resistance gene insert, we were able to
eliminate the majority of IL-2Rα producing cells via treatment with G418, a neomycin
analog. Treatment with G418 therefore allowed us to study VSMC nearly depleted of IL2Rα.
These findings are important in contributing to knowledge of the role of IL2-Rα
in VSMC function, which could later aid in developing treatments for intimal hyperplasia
and, in turn, atherosclerosis. In addition, knowing that the mice are only partially
knocked out is beneficial to future investigators working with these mice.
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CHAPTER 1
The Role of VSMC and IL-2 in Atherosclerosis
I. Introduction
Atherosclerosis
Atherosclerosis is the leading cause of death and disability in the Western world
(Singh et al. 2002). Over time, our society has seen increases in high-fat diets, sedentary
lifestyles, and obesity (Pahwa and Jilal 2020). Because of this, populations have become
more vulnerable to developing atherosclerosis. Fatty streaks, which form in the arterial
walls, develop into plaques (Herrington et al. 2016). Cardiovascular diseases such as
coronary heart disease and stroke, which occur from atherosclerosis, have affected
several world populations. Although the mortality rate of these diseases has declined over
the years, coronary heart disease still remains the top cause for premature adult mortality
worldwide (Herrington et al. 2016). Intimal hyperplasia is a precursor to the development
of atherosclerosis.
Intimal hyperplasia occurs when there is a large collection of cells in the tunica
intima. The high number of cells stems from proliferation and migration of smooth
muscle cells in response to injury or inflammation (Haudenschild 1989). VSMC
accumulation through proliferation and migration leads to intimal expansion, therefore
causing intimal hyperplasia. Intimal hyperplasia develops as follows. When the
endothelial cell layer is damaged, thrombosis occurs (Lemson et al. 2000). VSMC
proliferation-inhibiting factors such as heparan sulfate, nitric oxide, and prostacyclin
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decrease. In addition, thrombocyte release of heparinolytic enzymes aide in decreasing
proliferation-inhibitor concentrations (Lemson et al. 2000). Meanwhile, growthstimulating factors such as basic fibroblast growth factor, angiotensin II, and
catecholamines accumulate and promote VSMC proliferation (Lemson et al. 2000). Next,
VSMC migrate from the media to the intima. This migration is facilitated by the
degradation of the extracellular matrix, which contains heparan sulfate proteoglycans,
collagen, fibronectin, elastin, and other proteoglycans (Lemson et al. 2000). When
damage occurs, tissue-type plasminogen and kinase-type plasminogen activators degrade
the extracellular matrix and activate matrix metalloproteases. As the cells continue to
proliferate, platelet-derived growth factor (PDGF) aides in their migration to the intima
(Lemson et al. 2000).
Intimal hyperplasia leads to atherosclerosis; atherosclerosis is caused by plaque
buildup in the arteries, leading to thickening of the blood vessels; it then leads to loss of
blood and oxygen flow. The overall process consists of the formation of fatty streaks,
formation of atheroma, and then formation of the atherosclerotic plaques (RafieianKopaei et al. 2014). This often results from chronic endothelial injuries that occur
through hypertension, smoking, an inactive lifestyle, a high cholesterol diet, and obesity
(Rafieian-Kopaei et al. 2014). When fatty streaks form, cholesterol-rich low density
lipoproteins (LDL) are trapped; this therefore increases the amount of LDL in the intima,
which then leads to spontaneous oxidation (Rafieian-Kopaei et al. 2014). These oxidized
particles activate monocytes and T lymphocytes, both of which flow into the vascular
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intima through the arterial walls. When VSMC migrate into the lesion site, cytokines and
growth factors are released; this leads to the formation of the atherosclerosis plaque,
reducing blood flow (Rafieian-Kopaei et al. 2014). Atherosclerosis leads to conditions
such as coronary heart disease, chronic kidney disease, and carotid artery disease.
Although millions of patients receive treatment every day for narrowed or
occluded arteries, it is essential to find more effective methods. Currently, balloon
angioplasties and stent implantations are used; however, these may lead to in-stent
restenosis (Kim et al. 2018). To counteract these effects, stents are covered in drugs, such
as rapamycin, that inhibit VSMC proliferation. The issue with these nonspecific drugs is
that they also suppress re-endothelialization, which may lead to thrombosis (Kim et al.
2018). Studying the proliferation and migration of VSMCs is therefore of significance
since these functions lead to intimal hyperplasia in vivo.
VSMC Role in Atherosclerosis: Differentiation into Quiescent and Proliferative
Phenotypes
Vascular smooth muscle cells play a critical role in intimal hyperplasia. Their
primary function is to contract, therefore controlling vessel diameter, and regulating
blood flow (Gomez and Owens 2012). The artery wall is composed of the adventitia,
which is the outermost layer of the wall, the tunica media, and the innermost tunica
intima (Davies and Hagen 1994). The adventitia consists of fibroblasts in connective
tissue, with collagen and elastin (Davies and Hagen 1994). The medial layer is composed
of VSMC, which are densely grouped together in an interstitial matrix; this matrix
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includes proteoglycans in addition to collagen and fibronectin (Newby and Zaltsman
2000). The basement membrane separates the media and tunica intima. It consists of
collagen, laminin, and heparan sulfate proteoglycans such as perlecan (Newby and
Zaltsman 2000). Finally, the tunica intima is composed of a thin layer of endothelial
cells, which are on the basement membrane.
VSMC are an important target in developing treatments for atherosclerosis and
intimal hyperplasia. They have been shown to be extremely flexible with their ability to
quickly respond to injury and inflammation. This response, when smooth muscle cells
“switch” from a quiescent to proliferative phenotype, is aptly called phenotype
switching,. In the quiescent (contractile) phenotype, the cells are spindle-shaped and
elongated. They are non-proliferative and non-migratory; however, under inflammatory
conditions, quiescent cells can shift into a proliferative phenotype. Quiescent cells also
produce less h-caldesmon, collagen and meta-vinculin than proliferating VSMC (Rensen,
Doevendans and Van Eys 2007). Cells in the proliferative (synthetic) phenotype are
shorter and more rounded. (Rensen, Doevendans and Van Eys 2007). In addition, they
produce four to five times more extracellular matrix proteins than quiescent cells, and
their proliferation rates are increased by at least 10% (Lemson et al. 2000). In intimal
hyperplasia, as discussed before, there is an increased number of cells in the proliferative
state compared to the quiescent; with that, there are higher levels of matrix deposition,
and more cells found in the intima (Lemson et al. 2000). It is important to note that cells
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may contain features of both phenotypes; instead of being set in one phenotype, rather,
there is a gradient in phenotype expression.

Figure 1. Phenotypic switching of VSMCs from proliferative to quiescent states.
Proliferative cells can be seen to the left of the arrow, with quiescent cells on the right.
Created in Biorender.com.
IL-2 and its Role in Atherosclerosis
Interleukin-2 (IL-2) is most known to regulate T cell homeostasis; however, our
laboratory has previously shown that IL-2 may also play a role in VSMC function
(Arumugam et al. 2019). In previous studies, Miller et al. found that IL-2 is retained in
the arterial extracellular matrix through heparan sulfate proteoglycans. The authors
determined that IL-2 might be of importance to VSMC survival, as IL-2 KO mice lost
smooth muscle cells over time (Miller et al. 2012). Recently, our laboratory showed that
IL-2 increases expression of the survival-related protein FoxO3a in VSMC. FoxO3a is a
forkhead transcription factor regulated by the serine/threonine kinase Akt, which is
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responsible for phosphorylation of targets that contribute to cell proliferation, survival,
and differentiation (Allard et al. 2008). When akt is silent, VSMCs are quiescent, and
FoxO aides in cell survival. We showed that while VSMC growth factors such as PDGF
promote akt activation and proliferation, IL-2 shifts the balance towards FoxO and
survival (Arumugam et al. 2019). In addition, preliminary data showed that Bcl-xL
expression, an anti-apoptotic protein found in intimal VSMCs (Perlman et al. 1997), was
found to increase with addition of IL-2.
The IL-2 receptor is a heterotrimeric protein with α (CD25), β (CD122), and γ
(CD132) subunits. Arumugam, et al found that VSMC express all three subunits of the
IL-2 receptor (IL-2R). In addition, they found that depending on the phenotype, IL-2Rα
varied in expression and localization in the cells. This was a novel finding. Proliferating
VSMC expressed lower amounts of IL-2Rα in comparison to the quiescent phenotype
(Arumugam et al. 2019). IL-2Rα was also observed in the filopodia of proliferative cells,
while in quiescent cells, it was more concentrated around the cell body (Arumugam et al.
2019). Little is known about the localization of the IL-2Rα receptor. Data to be presented
in this thesis suggest that nuclear localization of IL-2Rα promotes quiescence in VSMC.
Previous studies from our laboratory suggested that IL-2 may play a role in
VSMC proliferation and migration. Our laboratory has found that IL-2 binds to heparan
sulfate and is present in the extracellular matrix surrounding VSMCs (Wrenshall and
Platt 1999). In addition, it associates with endothelial and smooth muscle cells within the
arterial wall. Interestingly, IL-2 KO mice were found to lose smooth muscle cells over
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time (Miller et al. 2012). More recent data, presented in this thesis, suggests that the IL2Rα localizes to the nucleus in quiescent, but not proliferating, VSMC. Understanding
the role of IL-2Rα in VSMC proliferation and migration, and how its localization impacts
these functions, may lead to new approaches for the treatment of intimal hyperplasia.
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CHAPTER 2
IL2-Rα Localization to the Nucleus is Dependent on VSMC Phenotype
I. Introduction
Vascular smooth muscle cells are involved in the development of plaques. Intimal
hyperplasia, which is an accumulation of smooth muscle cells in the tunica intima,
typically occurs in the blood vessels prior to the development of atherosclerosis. When
injury or inflammation occurs, VSMC proliferate and migrate from the media to the
intima of the arterial wall, causing a narrowing of the vessel lumen. There is a
relationship between VSMC and atherosclerosis – as discussed previously, VSMC are
capable of phenotype switching in response to injury and inflammation.
Previous studies have shown that IL-2 promotes proliferation and migration of
VSMC, and as previously discussed, that VSMC expresses all three subunits of IL-2Rα.
Our laboratory found that there was lower expression of IL-2Rα in proliferating VSMC
in comparison to quiescent VSMC. When we looked closer at the cells that expressed
each phenotype, immunofluorescent staining suggested that quiescent VSMC expressed
IL-2Rα in their nuclei. However, the antibody we used was weak, as it needed tyramide
signal amplification (TSA) for adequate detection. Based on this initial observation, we
hypothesized that IL-2Rα localizes to the nucleus in quiescent VSMC, and in this
location may impact VSMC proliferation.
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II. Results
Due to the weak antibody used, and TSA needed to visualize the staining, we first
used four different antibodies (rabbit anti-human polyclonal anti-IL-2Rα antibodies from
Bioss Antibodies, BosterBio, MyBioSource, LSBio) to determine whether IL-2Rα was
present in the nucleus of vascular smooth muscle cells. As shown in Figure 2, we stained
VSMC with 4 distinct anti-IL-2Rα antibodies, specific to various epitopes on the receptor
(see Table 1). The nucleus was demarcated using DAPI. When the images merged, the
receptor could be seen in the nucleus of VSMC.
Anti-IL-2Rα Antibody

Epitope

Boster

N-terminus, amino acids 39 - 57

LS Bio

C-terminus, amino acids 223-272

My BioSource

IL-2Rα

Bioss

C-terminus, amino acids 258 - 268

Table 1. Epitopes of anti- IL-2Rα antibodies from commercially available sources.
To further prove that IL-2Rα was present in the nuclei of quiescent cells, we
isolated membrane, cytoplasmic, and nuclear fractions of quiescent VSMC and probed
for IL-2Rα using Western blot analysis. Figure 3 shows that the majority of IL-2Rα was
localized to the nucleus of VSMC.
In order to show that the antibody tested was specifically recognizing IL-2Rα, we
preabsorbed IL-2Rα with the immunizing peptide used to generate the antibody.
Presabsorption of anti- IL-2Rα with the immunizing peptide abrogated staining. In
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addition, we decreased IL-2Rα expression in VSMC using siRNA. As seen in Figure 4,
knock down of IL-2Rα message with siRNA greatly decreased detection of nuclear IL2Rα.
VSMC are phenotypically different if grown in SMCM with 2% FBS
(proliferative media; see Materials and Methods) compared to serum free DMEM
supplemented with insulin, selenium, and transferrin (ITS) (quiescent media) (Kisiday et
al. 2005). To determine whether localization of IL-2Ra differed in proliferating vs
quiescent VSMC, VSMC were grown in each of the aforementioned media and
localization of IL-2Ra was assessed using indirect immunofluorescence. Figure 5a shows
that when compared to the cells in SMCM, the cells grown in ITS displayed more IL-2Rα
in the nucleus. Figure 5b shows a histogram of 9,000 – 11,000 VSMC cultured under
proliferating or quiescent conditions and stained with anti- IL-2Rα. As shown by the
black line, the cells grown in ITS had a higher number of nuclei that expressed IL-2Rα.
From this, it is suggested that there is more found in the nucleus of cells that are
phenotypically quiescent.
The nuclear localization of IL-2Rα in quiescent VSMC led us to ask whether the
receptor was indeed absent from proliferating cells or, alternatively, was not recognized
by the anti- IL-2Rα antibody due to post-translational modifications, particularly
glycosylation, that might occur with proliferation. IL-2Rα is known to be heavily
glycosylated, with several N and O glycosylation sites (Greene and Leonard 1986). As a
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IL-2Rα

DAPI

Merge

Boster

LS Bio

My BioSource

Bioss

Figure 2. IL-2Rα is expressed in the nuclei of VSMC. VSMC were isolated from
human aortas and grown in serum free media; afterwards, they were fixed and stained
with 4 distinct anti- IL-2Rα primary antibodies as shown. They were then probed with the
appropriate secondary antibodies and imaged using an epifluorescent microscope. The
above data are representative of 3 separate experiments.
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50 kD
IL-2Rα
37 kD
Fibrillarin

Figure 3. IL-2Rα is localized to the nucleus of quiescent VSMC. VSMC were cultured
in serum free media to induce quiescence. Cells were lysed and fractionated using a
commercially available kit (Cell Signaling Technology, MA). Lysates were subjected to
Western blot analysis and probed with anti-IL-2Rα antibodies. The purity of the nuclear
fraction was assessed using fibrillarin, which localizes to the nucleolus. This experiment
is representative of 3 separate experiments.

first step in determining whether the pattern of IL-2Rα in proliferating VSMC was due to
changes in expression versus detection, we re-probed these cells with anti-IL-2Rα from
Bioss, since this antibody gave some cytoplasmic signal in quiescent VSMC (Figure 2).
The epitopes recognized by the antibodies from Boster versus Bioss are quite distinct (see
Table 1). The antibody from Bioss recognizes an epitope at the C terminus, whereas the
antibody from Boster recognizes an epitope within the N terminus. When probed with
anti-IL-2Rα from Bioss, cytoplasmic and membrane localization was detected in
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siRNA IL-2Rα

Lipofectamine

IL-2Rα

IL-2Rα + peptide

Figure 4. The IL-2Rα antibody (BosterBio) is specific to detection of the receptor.
(top) VSMC were treated with 25 nM siRNA or vehicle only for 48h, and then later
stained with the anti-IL-2Ra antibodies from Boster and the appropriate secondary.
(bottom) Human VSMC were cultured in serum free media supplemented with ITS for 6
days. They were fixed and stained with anti-IL-2Rα (after being pre-absorbed with
immunizing peptide), and then probed with an HRP conjugated secondary antibody,
finishing with tyramide signal amplification. Nuclei were identified with DAPI. Scale bar
= 200 microns. These data are representative of 4 separate experiments.
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proliferating VSMC (Figure 6a). However, expression in the nucleus remained low with
both antibodies.
Because cytoplasmic vs membrane localization is difficult to distinguish in
permeabilized cells, we probed fractionated VSMC lysates with the anti- IL-2Rα from
Bioss. Based on this fractionation, the majority of IL-2Rα detected by the antibody from
Bioss was in the membrane (Figure 6b). Additional experiments, outside the scope of this
thesis, showed that the antibody from BosterBio does not recognize the membrane form
of IL-2Rα due to differential glycosylation.
Because we observed nuclear localization of IL-2Rα when VSMC are in the
quiescent phenotype, we wanted to see if IL-2Rα would localize to the nucleus if cells
were placed under other conditions, such as cellular stress, in which cells do not
proliferate. We used tunicamycin to induce stress to the endoplasmic reticulum (ER),
bleomycin to induce genotoxic stress, and hydrogen peroxide to cause oxidative stress in
VSMC. As seen in Figure 7, conditions of cellular stress increased nuclear localization of
IL-2Rα.
The following data is based on VSMC in vitro. To determine whether IL-2Rα
localized to the nucleus in situ, we examined normal and diseased human arteries for
expression of IL-2Rα by Western blot. We acknowledge that not all cells in the arterial
wall are VSMC, but they will comprise the majority. As seen in Figure 6B, the anti-IL2Rα antibody from Bioss recognized a 50kD form of IL-2Rα in the membrane fraction
and a 45kD form in the nuclear fraction. The anti-IL-2Rα from Boster strongly
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A

SMCM

ITS

85

B

Number of cells

64

43

21

0
4

10

5

10

10

Cy5 intensity
IL2RA AF647

854 ITS 0.csv

6

854 SMCM 0.csv

Figure 5. Nuclear localization of IL-2Rα is increased in quiescent vs proliferating
VSMC. (A) VSMC were grown in SMCM and ITS for 3 days, fixed, and stained with
IL-2Rα (BosterBio), followed by the appropriate Cy5 conjugated secondary antibody. (B)
The histogram represents the summation of 9000 (ITS) and 11,000 (SMCM) VSMC.
Cells were imaged using a Cytation (Biotek) imaging plate reader and data was processed
using FCS Express 7 flow cytometry software. These data are representative of 3 separate
experiments.
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A

Bioss

Boster
B

IL-2Rα
50 kD (Bioss)
100 kD Na-K-ATPase
75 kD -

Figure 6. Differential detection of IL-2Rα using antibodies recognizing distinct
epitopes. (A) VSMC were cultured in SMCM for 72 hours, fixed with methanol, and
stained with anti-IL-2Rα from BosterBio and Bioss. (B) The Western blot displays the
presence of IL-2Rα in the membrane, detected using the anti-IL-2Rα antibody from
Bioss. Smooth muscle cell lysates were utilized. Blot was imaged using the ChemiDoc
and Image Lab. Control Western blot uses Na-K-ATPase antibody from Proteintech.
These data are representative of over 5 experiments.
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Control

Stress

ER

Genotoxic

Oxidative

Figure 7. IL-2Rα localizes to VSMC nuclei under conditions of stress. Cells were
grown in DMEM for 72 hours and treated with tunicamycin for endoplasmic reticulum
(ER) stress, bleomycin for genotoxic stress, and hydrogen peroxide for oxidative stress.
IL-2Ra was detected as previously described. These data are representative of 4 separate
experiments.

recognized a 45kD form in the nucleus but did not recognize the 50kD form in the
membrane fraction (Figure 3). Based on these data, we used the latter size differences to
identify membrane vs nuclear IL-2Rα in lysates of diseased and normal human arteries.
In comparing tissue from an abdominal aortic aneurysm (AAA) to a normal artery, the
membrane form predominated in the aneurysmal tissue and the nuclear form
predominated in the normal tissue. In a second specimen from a popliteal aneurysm, the
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membrane form predominated at the site of the aneurysm. However, more “normal”
tissue distal to the aneurysm weakly expressed the nuclear form. In the adjacent popliteal
vein, where inflammation would be markedly decreased, the nuclear form predominated.
We chose aneurysmal tissues given their high level of inflammation, however
atherosclerotic tissue without aneurysmal changes revealed similar findings (not shown).
In summary, these data suggest that quiescent VSMC, cultured without serum in vitro or
present in non-inflamed arteries in vivo, express IL-2Rα mainly in the nucleus. In
contrast, VSMC exposed to proliferative or inflammatory stimuli in vitro or in vivo
express IL-2Rα mainly in the cell membrane.

Figure 8. The “nuclear” form of IL-2Rα predominate in normal arteries and the
membrane form predominates in inflamed arteries. Tissue lysates were prepared from
diseased or normal human arteries and probed with anti-IL-2Rα antibodies as previously
described. These data are representative of over 5 experiments.
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Based on our findings that IL-2Rα localizes to the nucleus of quiescent cells, we
next asked, using VSMC isolated from IL-2Ra KO mice, how the absence of IL-2Rα
might impact proliferation and migration of VSMC. Proliferation and migration are
characteristics of synthetic/proliferative VSMC, and these functions are implicated in the
development of intimal hyperplasia. We first measured proliferation of cells using a click
chemistry-based proliferation assay, in which dividing cells incorporate the nonradioactive nucleoside analog 5-ethynyl-2’-deoxyuridine (EdU) (Wong et al. 2019). Click
chemistry is termed from when alkyne and azide groups “click” together when exposed
to catalytic copper (Hein et al. 2008). The alkyne that attaches to the nucleoside analog is
detected by the azide, which is bound to a fluorescent marker (Hein et al. 2008).
KO VSMC displayed increased baseline and stimulated proliferation when
compared with WT VSMC. These data suggest that nuclear localization of IL-2Ra
promotes quiescence; if there is no IL-2Rα to localize into the nucleus, however, then the
cells will assume a proliferative phenotype. The data in Figure 9 may suggest that IL-2Rα
could play a role in inhibiting VSMC proliferation.
We then tested the impact of IL-2Rα on migration by testing migration of WT and
IL-2Rα KO VSMC. To measure migration, we used a Boyden chamber assay in which
VSMC are cultured on a filter and stimulated to migrate through it using a chemotactic
agent in the media. Figure 10 shows that, in comparison to the WT cells, the cells without
the receptor present had higher numbers of migrating cells both at baseline and when
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Figure 9. IL-2Rα deficient VSMC exhibit increased proliferation when stimulated
with FBS. were incubated for 72h with increasing concentrations of FBS. EdU was
added for the last 24h and its incorporation was detected using click chemistry. Total
cells were counted using the nuclear stain DAPI. Cells were counted using an imaging
plate reader. These data are representative of over 5 experiments.

stimulated by PDGF. This result suggests that the receptor plays a role in regulating cell
proliferation and migration.
We next wanted to see if we could alter nuclear localization of IL-2Rα using a
peptide. We chose to use a peptide because it is specific to the receptor and should have

20

minimal off target effects. To produce a peptide mimetic that might alter nuclear
localization of IL-2Rα, we first needed to determine which sequences might be causing
nuclear localization of the receptor. To do so, we used in silico analyses to find
DNA binding and nuclear localization sequences. The results showed that 12 amino acids
in the C terminus were predicted to bind DNA. A second analysis showed that 6 of these
amino acids were predicted to be a nuclear localizing sequence. From these data, we

number of migrating cells

created a peptide that consisted of the DNA binding sequence (C12AA); we hoped that
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Figure 10. IL-2Rα deficient VSMC exhibit increased migration in response to
PDGF. WT and KO-G VSMC were grown in DMEM and plated. 18-24 hours after being
plated, 50 ng/ml PDGF was added to the bottom chamber to stimulate migration. VSMC
nuclei were stained with Sytox, imaged using an epifluorescence microscope, and then
quantified using ImageJ. These data are representative of over 5 experiments.
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we hoped that this peptide would compete with the receptor in binding to the DNA or
nuclear localization sites. Because of this, we hypothesized that the peptide mimetic
would lower nuclear localization of IL-2Rα.

0

10 uM peptide

24h

48h

72h

100 uM peptide

Figure 11. VSMC treated with a peptide mimetic of the C terminus of IL-2Rα
express IL-2Rα in the nucleus. (top) VSMC were treated with 100 uM C12AA for up to
72h as noted above. IL-2Rα was detected using anti-IL-2Rα antibodies from Boster.
(bottom) VSMC were treated with TAMRA labeled C12AA (red) and imaged using
confocal microscopy. Nuclei were detected using Sytox (green). These data are
representative of over 5 experiments.
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Figure 11 shows the results of our treating VSMC with increasing durations of
C12AA. The upper panel of Figure 11 shows that the peptide mimetic increases (rather
than decreases) nuclear localization of IL-2Rα. The bottom panel demonstrates that a
fluorophore-labeled peptide enters the cell and appears to enter the nucleus. Although we
do not yet understand why C12AA increases IL-2Rα localization to the nucleus, we
continued to use this peptide to see how increased nuclear localization impacts VSMC
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function and phenotype. Once we found that C12AA increased nuclear localization of IL-
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Figure 12. Treatment of VSMC with C12AA, which increases nuclear localization of
IL-2Rα, inhibits migration and proliferation of VSMC. Cells were grown in DMEM
and treated with peptide for 72h (proliferation) or 18h (migration). Proliferation and
migration were assessed as previously described. This experiment is representative of
over 5 experiments.
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2Rα, we asked how this peptide affected VSMC migration and proliferation. As shown in
Figure 12, the number of unstimulated cells remained relatively stable. The number of
proliferating and migrating cells, however, decreased with increasing concentrations of
peptide used. This suggests that increased nuclear localization of IL-2Rα inhibits VSMC
proliferation and migration.
III. Summary and Discussion
In this study, we have shown that IL-2Rα localizes to the nucleus in quiescent
VSMC. We also demonstrated that IL-2Rα is localized to the nucleus when VSMC are
exposed to various types of cellular stress. We have generated evidence from westerns,
immunofluorescent staining, and exposing the VSMC to stressful conditions in order to
support our claim. We have shown that IL-2Rα could play a part in VSMC proliferation
and migration.
There are several theories as to how the receptor could be acting in the nucleus, to
play a role in VSMC proliferation and migration. The receptor could possibly be a
chromatin remodeling factor or a transcription factor. The mechanism of how nuclear IL2Ra inhibits proliferation will be the subject of future studies.
How localization of IL-2Rα is controlled is also an important area of
investigation. Our laboratory has preliminary data (not shown) suggesting that IL-2Rα
could be moving in and out of the nucleus by way of phosphorylation. We have seen that
phosphorylation increases nuclear localization; this could be similar to FOXO3A, which
moves in and out of the nucleus based on phosphorylation.
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FOXO3A interacts with several different kinases, which causes it to translocate to
the cytoplasm. On the other hand, interaction with other kinases cause it to undergo
phosphorylation at specific residues, which induce nuclear localization and
transcriptional activity (Wang et al. 2017). Acetylation also occurs, which aids in
transcriptional activity and expression of stress resistance genes. It has been found that
phosphorylation and acetylation happen at the same time and could possibly have an
effect on each other (Wang et al. 2017). This information is relevant because FOXO3A
and other proteins that shuttle between the nucleus and cytoplasm serve as models for
mechanisms that may alter localization of IL-2Rα.
Data in this thesis shows that the anti-IL-2Rα antibody from Boster is present in
the nucleus of quiescent VSMC, while the antibody from Bioss is detectable in the
membrane of proliferating VSMC. There are several possibilities as to why the anti-IL2Rα antibody from Boster does not detect membrane IL-2Ra; however, our laboratory
has found, in preliminary studies, that glycosylation could be playing a role. It is possible
that the membrane form of IL-2Rα is more heavily glycosylated and that this
glycosylation could be blocking the N terminal epitope recognized by the antiIL2Ra from Boster. In turn, the nuclear form of the receptor may be less glycosylated.
This hypothesis is supported by our finding that the membrane form of IL-2Rα is larger
than the nuclear form (50 vs 45 kD). Glycosylation of the membrane form of IL-2Rα may
serve as a means to promote membrane localization and block nuclear localization.
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IL-2R is a tripartite receptor; however, our studies are focused on the alpha
subunit. When the alpha subunit binds to the beta and gamma subunits, affinity for IL-2
increases. However, the findings presented here are independent of IL-2. Although
preliminary data suggests that IL-2 increases nuclear localization of IL-2Rα, many other
stimuli also increase nuclear localization (Figure 7). These findings are similar to a study
conducted by Deho et al., who found that the alpha subunit controls mast cell production
independent of IL-2.
If we can determine the mechanism by which IL-2Rα localizes to the nucleus and
inhibits proliferation, then perhaps therapies can be generated that prevent plaques from
forming as quickly. If cells can be manipulated to remain in the quiescent phenotype,
proliferation and migration would decrease, therefore slowing the formation of intimal
hyperplasia.
IV. Materials and Methods
Immunofluorescence
VSMC cells were seeded in 8-well chamber slides, then cultured in 10% DMEM
(proliferative media) or ITS-supplemented DMEM (quiescent media) for 72h at 37°C.
The cells were fixed in ice-cold methanol and stained. Slides were stained with a primary
antibody and then an appropriate secondary antibody. All antibodies were validated by
Western blot. VSMCs were imaged using the EVOS FL epifluorescence microscope
(Thermo Fisher Scientific).
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Protein extraction
Cells were grown to approximately 70-80% confluence in SMCM or ITS media.
The media was aspirated, and the cells were washed with PBS. Once PBS was removed,
RIPA lysis buffer + protease inhibitors were added to each plate, and a cell scraper was
used to scrape the cells into a conical tube. The lysates were incubated on ice. They were
then sonicated, incubated on ice again, and centrifuged at 4ºC. The supernatant,
containing soluble protein, were placed in separate tubes and stored at -80ºC. Lysates
were measured for protein concentration by BCA prior to use.
Western blotting
Protein amounts of cell samples were determined by BCA to ensure equal
amounts per lane, prior to being treated by SDS-PAGE. After being run on a gel, proteins
were transferred to a PVDF membrane and incubated with 5% nonfat milk in TBST
[0.5% Tween 20, 10 mM Tris (pH 8.0), 150 mM NaCl) for one hour, rocking at room
temperature. The membrane was then rocked overnight at 4°C in blocking buffer with
primary antibodies (Boster, 1:1000) against IL-2Rα. It was washed three times for ten
minutes each using TBST, and then incubated with the secondary antibody (horseradish
peroxidase-conjugated anti-rabbit) at dilution 1:10,000 for one hour, rocking at room
temperature. The membrane was washed three more times for ten minutes each, and then
developed for five minutes, rocking with Luminata Crescendo Western HRP substrate
(Millipore Sigma).
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VSMC proliferation
Proliferation was measured by incorporation of EdU, which was then assessed
using click chemistry. Once cells were cultured at 37ºC in SMCM or ITS media, they
were transferred to a 96 well plate and stimulated to proliferate for 72h with either PDGF
or FBS. VSMC were treated with EdU for the last 24 hours of the incubation period. The
cells were fixed in paraformaldehyde and EdU was detected using the following labeling
solution (THPTA, CuSO4, Cy3 picolyl azide, Na ascorbate). Incorporation of EdU were
measured using a fluorescence plate reader (Cytation, Biotek).
VSMC migration
Migration was assessed using the Boyden chamber assay (Arumugam et al. 2019).
VSMCs were plated in the Boyden chambers, which are filter inserts placed in 24-well
plates. VSMC were plated into the upper well formed by the insert. VSMC were allowed
to settle for 12 -18h and stimulated to migrate through the filter by adding a chemotaxis
agent (PDGF) to the lower chamber. VSMC were allowed to migrate for 6 hours, and
then the cells on the filter inserts were fixed with methanol at -20ºC. The cells on the top
side of the filter were removed using a cotton swab, while cells migrating through to the
underside of the filter were washed with PBS, and then stained with Sytox. The cells
were imaged using the EVOS FL epifluorescence microscope (Thermo Fisher Scientific),
and then counted using Image J (Arumugam et al. 2019).
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CHAPTER 3
Incomplete knock out of IL-2Rα knock out mice
I. Introduction
VSMC are found to play a role in atherosclerosis; as discussed in Chapters 1 and
2, IL-2R may also contribute to VSMC phenotype switching, which in turn could be a
point of treatment against plaque development. The source of VSMC in these studies
stems primarily from mice, in addition to human tissue donations. Mice are important
model organisms due to their genetic similarity to humans, in addition to their anatomical
and physiological likeness (Bryda 2013). Like humans, mice have about 30,000 genes,
95% of which are shared between both species. It is advantageous to use mice, due to
their quick reproduction and high numbers of offspring (Bryda 2013).
Data from Chapter 1 indicated that IL-2Rα is expressed in the nucleus of VSMC.
To help define the function of nuclear IL-2Rα, we isolated VSMC from IL-2Rα WT and
KO mice. Surprisingly, we found that IL-2Rα protein was expressed in KO VSMC. Our
findings outlined below show that commercially available IL-2Rα KO mice are not
complete knock outs, raising a cautionary note for investigators using these mice.
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II. Results
We acquired IL-2Rα KO mice to determine how IL-2Rα affects the function of
VSMCs. WT and KO mice were identified by genotyping using the protocol provided by
Jax mice. As a first step following isolation and culture of VSMC from each of these
mice, we examined expression of IL-2Rα protein. Figure 13 displays the use of 4
commercially available anti-IL-2Rα antibodies from Bioss Antibodies, BosterBio, and
LSBio to assess IL-2Rα protein in WT and KO VSMC. As shown in Figure 13, IL-2Rα
was detected in both WT and KO VSMC using each antibody.
To further support that there was receptor in the KO cells, we assessed IL-2Rα
protein expression by Western blot analysis. As shown in Figure 14, expression of IL2Rα protein in WT and KO cells is comparable. This supports the fact that the KO
VSMC are not fully knocked-out, with presence of the receptor in both cell
immunofluorescence staining and western blotting. It is also of note that all the bands are
the same size; this is important because IL-2Rα has multiple splice variants. By
comparing the WT and KO VSMC to human VSMC and T cells, we found that the KO
cells express full-length IL-2Rα.
To confirm that the anti-IL-2Rα antibody used was specific for its epitope and not
exhibiting any non-specific binding, we pre-absorbed the antibody with immunizing
peptide prior to staining. This preabsorption abrogated staining, demonstrating that
detection of protein by this anti-IL-2Rα antibody is specific to the IL-2Rα epitope (Figure
15).
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Figure 13. IL-2Rα is detected in WT and KO VSMC with use of antibodies. VSMC
were isolated from WT and KO mice, cultured, and then stained with three different antiIL-2Rα antibodies as noted. These data are representative of 3 separate experiments.
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Figure 14. Full length IL-2Rα is being expressed in KO VSMC isolated from mice.
Lysates were prepared from Jurkat T cells, WT VSMC, and IL-2Rα KO VSMC. Isolated
proteins were separated by SDS-PAGE and IL-2Rα was detected by Western blot
analysis. All bands fall between 37 and 50 kD, indicating protein being detected is fulllength IL-2Rα. This experiment is representative of over 5 separate experiments.

Given our results suggesting that VSMC isolated from IL-2Rα KO mice are
producing IL-2Rα protein, we asked whether we could detect the WT IL2RA gene in
genomic DNA isolated from KO VSMC. To increase the sensitivity of detection, we used
WT and KO primers both individually and together. While both primers used
simultaneously did not detect a WT product, use of the WT primer alone detected a band
of predicted WT size consistent with our WT controls (Figure 16). Use of the KO primer
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IL-2Rα

IL-2Rα + peptide

Figure 15. Preabsorption of anti- IL-2Rα with immunizing peptide abrogates
detection of nuclear IL-2Rα in VSMC. WT VSMC were stained with anti-IL-2Rα
with/without pre-absorption of the antibody with the immunizing peptide. These data are
representative of over 5 experiments.
alone detected the predicted IL2RA mutant gene isolated from KO but not WT VSMC.
Sequencing of the WT band from IL-2Rα KO VSMC confirmed the presence of IL-2Rα.
These results demonstrate that VSMC isolated from KO mice express the WT IL-2Rα
gene.
IL-2Rα KO mice were generated by replacing exons 2 and 3 of IL-2Rα with a
neomycin resistance gene insert as a selectable marker (Willerford, et al, 1995). Given
this information, we asked whether treatment of KO VSMC with G418 (a neomycin
analog) would decrease or eliminate IL-2Rα protein expression. We predicted that KO
cells would be resistant to G418 (assuming the Neo gene is transcribed) and WT cells
would be sensitive and therefore eliminated. To this end, we cultured WT and KO VSMC
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Figure 16. IL-2Rα KO VSMC express WT IL-2Rα DNA. DNA was isolated from
murine VSMC and tails. DNA was amplified using IL-2Rα primers per Jax protocol. The
WT primers amplify a 146 bp product, and the mutant a 280 bp product. Primer sets were
added together, or singly, as indicated. PCR was performed using these primers and
amplified products were separated electrophoretically in a 1.5% agarose gel containing
0.5 mg/ml ethidium bromide. PCR products were visualized using UV light and the
image was captured using ChemiDoc MP imaging. These data are representative of over
5 experiments.
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Figure 17. G418-treated KO VSMC display less IL-2Rα than WT VSMC. WT and
KO VSMC were grown in DMEM for 96 hours, with 2 mg/ml G418. Cells were stained
with IL-2Rα primary (BosterBio) and the appropriate secondary before imaging. These
data are representative of over 5 experiments.
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with increasing concentrations of G418. G418 nearly eliminated WT cells at a
concentration of 2 mg/ml (Figure 17). However, 85% of VSMC isolated from KO mice
survived G418 treatment. IL-2Rα production by these treated cells was significantly
diminished compared to WT VSMC as shown by immunofluorescence (Figure 17).
These data demonstrate that the Neo resistance gene is expressed in IL-2Rα KO
VSMC, and that treatment of KO VSMC with G418 killed susceptible WT cells and
significantly decreased IL-2Rα protein production.
While it is shown in Figure 17 that treatment of IL-2Ra KO VSMC with G418
nearly eliminated IL-2Ra producing cells, we wanted to confirm our results using a
different approach, specifically Western blot analysis. Figure 18 shows that lysates of
VSMC treated with G418 have less IL-2Rα in comparison to cells that have not been
G418-treated.
We found that VSMC isolated from KO mice expressed the wildtype IL2RA gene,
but the level of IL2RA gene seemed qualitatively low compared to the amount of protein
expressed. This incongruity prompted us to ask if KO VSMC were picking up receptor
from an exogenous source. Several studies have shown the presence of soluble CD25 in
conditions such as non-Hodgkin’s lymphoma, hepatocellular carcinoma, multiple
sclerosis, and coronary artery disease (Jo et al. 2010, Cabrera et al. 2010). Given these
reports, we wanted to see if FBS possibly contained IL-2Rα. We added FBS to serum
free media in concentrations of 0, 0.5, and 2% to see if KO VSMC cultured in FBS
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express more IL-2Ra protein. As shown in Figure 19, IL-2Rα KO VSMC cultured in FBS
express increased IL-2Rα when compared to those in serum free media.
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Figure 18. G418 decreases IL-2Rα protein expression in VSMC isolated from IL2Rα KO mice. VSMC, isolated from IL-2Rα WT and KO mice, were cultured under
serum free conditions in the presence/absence of G418 at 2 mg/ml. VSMC were
subsequently lysed and extracted proteins were separated by SDS-PAGE and analyzed by
Western blot for expression of IL-2Rα. Histone H3 was used to normalize the amount of
protein run for both samples. Relative intensity of the bands was generated using a
BioRad imager, by calculating the intensity of the histone H3 bands, and normalizing the
IL-2Rα to the baselines. This experiment is representative of 4 experiments.
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Figure 19. WT and KO VSMC display higher proliferation rates and expression of
IL-2Rα with higher concentrations of FBS. Cells were grown in DMEM for 3 days and
treated with varying concentrations of FBS. They were then imaged after being fixed and
stained with the according primary and secondary antibodies (BosterBio). These data are
representative of over 5 experiments.
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Based on the number of cells per field, the latter data suggested that KO cells
proliferated more than WT when exposed to FBS, consistent with our prior observations
(Figure 9). In addition, these cells were noticeably smaller in morphology (Figures 19,
20). KO VSMC were not only much smaller than WT cells, but they also took up less
DAPI (Figure 20). This observation is consistent with the finding that DNA content is
directly proportional to cell size (Amodeo & Skothiem 2016). In comparing nuclear area
and DNA content of WT and KO VSMC, however, we noted that the decrease in DNA
content was out of proportion to the decrease in nuclear area. KO nuclei were
approximately half the size of WT, but only had 1/6 the amount of DNA. This finding
suggests that KO VSMC are hypodiploid, which implies a severe dysregulation of cell
proliferation and/or division. Hypodiploid cells are mainly associated with an aggressive
form of acute lymphoblastic leukemia (Comeau & Mullighan 2017).
Because our data suggested that VSMC were taking up IL-2Rα from serum, we
assessed the presence of IL-2Rα in FBS by Western blot. For comparison, we included
purified IL-2Rα from a commercially available source that is comprised of amino acids
1-213. Soluble IL-2Rα, released from the cell surface by enzymatic cleavage, is cleaved
between amino acids 182 – 192 and is therefore smaller than the commercially available
protein. IL-2Rα was detected in FBS, however its molecular weight was approximately
45kD, consistent with full length IL-2Rα from VSMC lysates (Figure 21). Commercially
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Figure 20. IL-2Rα deficient VSMC are smaller and contain less DNA compared to
WT cells. (top) Phase and IL-2Rα overlay images from WT and KO VSMC, treated and
probed for IL-2Rα as in Figure 19. Scale bar = 100 uM. (bottom) Nuclei of VSMC from
Figure 19 were imaged for area and DAPI intensity using a Cytation imaging plate reader
(Biotek). Data accrued from these images were then processed using flow cytometry
software. These data are representative of over 5 experiments.
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Figure 21. IL-2Rα is found in FBS. Purified IL-2Rα protein and FBS were separated by
SDS-PAGE and analyzed by Western blot for expression of IL-2Rα. The purified protein
was produced in HEK-293 cells and is truncated at amino acid 213. These data are
representative of 4 experiments.

available IL-2Rα was approximately 37 kD. These results suggest that IL-2Rα in serum is
full length IL-2Rα and not the soluble, truncated form.
III. Summary and Discussion
In this study, we have provided evidence from immunofluorescence staining,
western blotting, and PCR showing that commercially available IL-2Rα KO mice are not
fully knocked out. Although other studies have used these mice to study the IL-2/IL-2R
system, our results do not necessarily negate those findings. In fact, our data suggest that
the phenotype of a complete IL-2Rα KO mouse would be more severe than that of mice
currently used. However, for future studies, researchers should be careful if they are
considering using these mice for experiments.
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Although our data shows that the IL-2Rα mice are incompletely knocked out, the
mechanism behind the incomplete KO is not known. Knockout mice are usually
generated by replacing a portion of the coding region of the gene by a drug resistance
marker. For correct insertion of the drug resistance marker and deletion of the targeted
coding region, homologous recombination must occur at both the 5’ and 3’ ends of the
DNA to be inserted. If homologous recombination only occurs on the 5’end, then the
segment of DNA is inserted but the coding region is not deleted (LePage, et al, 2006). In
addition, the neomycin resistance coding sequence and its PGK1 promoter can have
unintended consequences on the targeted gene and on adjacent genes if they are left in the
gene. Given these issues, some recommend using a Neo insert that is flanked via crespecific recombinase, so that the insert may be deleted (LePage, et al, 2006). However,
this technology had not yet been invented at the time the IL-2Rα KO mice were
generated.
The ability to clear IL-2Rα protein with G418 revealed that VSMC take up IL2Rα from serum. Given the low level of IL-2Rα detected in IL-2Rα KO cells cultured in
FBS, however, the majority of IL-2Rα seen in KO cells appears to be coming from
murine IL-2Rα production. The molecular weight of IL-2Rα in bovine serum indicates
that the cells are taking up full length, rather than soluble, IL-2Rα. This is a novel
finding. The presence of full-length IL-2Rα in FBS suggests that IL-2Rα may be coming
from exosomes or microvesicles rather than enzymatic cleavage of a soluble, truncated
form. Soluble IL-2Rα is generated when IL-2Rα is cleaved at the surface of the cell by a
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membrane metalloproteinase (Durda et al. 2015). This data is interesting in that cells may
be giving IL-2Rα (whether cleaved or uncleaved) to each other; cells could therefore
influence the behavior of other cells.
In a previous study, it was found that human T cell leukemia cells spontaneously
released high amounts of the receptor, which was detected in culture supernatants (Rubin
et al. 1985). While the full-length receptor was found associated with cell lysates, a
smaller, soluble version was also found. In addition, both T and B cell lines were found
to produce soluble IL-2R in vitro. Rubin et al. hypothesized that the soluble IL-2R may
play a role in regulating the inflammatory response, by binding soluble IL-2. We have not
identified any studies, however, that demonstrate or postulate uptake of soluble IL-2Rα
by other cells.
In summary, we have determined that commercially available knockout mice are
not fully knocked out. We found that treating VSMC with G418 decreases the expression
of IL-2Rα. We also found that there is IL-2Rα is present in serum, suggesting that IL2Rα production from one cell or cell type could be influencing other cells.
IV. Materials and Methods
The methods below only include those not already described in Chapter 2.
DNA extraction
Mice were obtained from Jackson Laboratories. Tail clips were enzymatically
treated overnight in a 55°C water bath using tail extraction buffer [50 mM Tris-HCl (pH
7.4), 100 mM EDTA, 100 mM NaCl], 20% SDS, and 10 mg/ml Proteinase K (Alfa
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Aesar, Lot#T08G006). DNA was extracted using 5M NaCl, ethanol, and TE buffer [1M
Tris base pH 10-11 (Fisher BioReagents, Lot#198843), 0.5M EDTA (Sigma,
Lot#SLBP6617V), H2O]. It was then suspended in water and treated with 10 ug/ml
RNAse A (Sigma, Lot#027K1108) at 37°C for 30 minutes. The DNA was precipitated
using 3M NaAC and ethanol. Purity values were obtained using the Synergy H1 Hybrid
Reader (BioTek).
PCR
Mice were genotyped using the protocol provided by Jackson Laboratories.
EconoTaq PLUS GREEN 2X Master Mix (Lucigen) and IL-2Rα WT (CD2KO-0461,
CD2KO-0462) and KO (CD2KO-6916, CD2KO-6917) primers (Integrated DNA
Technologies) were used for DNA amplification. The DNA was amplified using the
3Prime thermocycler (Techne) with the following touchdown protocol (developed using
Korbie, Mattick 2008).
DNA electrophoresis
1.5% agarose (Fisher Scientific, Lot#124315) and 10% TBE buffer [Tris base
(Fisher BioReagents, Lot#198843), Boric acid (Fisher Scientific, Lot#140681), EDTA
pH 8.3 (Sigma, Lot#SLBP6617V)] were mixed in a flask and microwaved, stirred, and
microwaved once more. Once settled to warm temperature, ethidium bromide (Fisher
BioReagents, Lot#116199) was added, the solution swirled and then poured into the
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1
2
3
4
5
6
7
8
9
10

94°C
94°C
65°C down to 51°C,
increments of 1
72°C
94°C
53.4°C
72°C

3:00
0:20
0:30
0:15
Go to Step 2 15 times total
0:20
0:30
0:15
Go to Step 6 20 times total

6°C forever

Table 2. Touchdown amplification protocol. The Touchdown amplification protocol
begins with an annealing temperature above the optimal melting temperature of the
primers, and progresses lower through cycles. The second part of the run consists of a
standard amplification stage (Korbie, Mattick 2008).
casting tray to solidify. Once solidified, the gel buffer was poured over top of the gel, and
used to wash out the wells. The DNA ladder and samples were loaded and run for 1 hour
at 100 V. The gel was read using a ChemiDoc Imaging System (Bio-Rad).
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